PDF
File
Kurs
0,00%
Likviditet
0,14 MSEK
Kalender
| Tid* | ||
| 2025-03-13 | 13:30 | Kvartalsrapport 2025-Q3 |
| 2025-01-08 | N/A | Extra Bolagsstämma 2025 |
| 2024-11-28 | - | Kvartalsrapport 2025-Q2 |
| 2024-10-12 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2024-09-16 | - | Kvartalsrapport 2025-Q1 |
| 2024-06-26 | - | Bokslutskommuniké 2024 |
| 2024-03-27 | - | Kvartalsrapport 2024-Q3 |
| 2023-12-21 | - | Kvartalsrapport 2024-Q2 |
| 2023-11-15 | - | Extra Bolagsstämma 2024 |
| 2023-10-27 | - | Årsstämma |
| 2023-10-13 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2023-09-20 | - | Kvartalsrapport 2024-Q1 |
| 2023-06-23 | - | Bokslutskommuniké 2023 |
| 2023-05-09 | - | Extra Bolagsstämma 2023 |
| 2023-03-28 | - | Kvartalsrapport 2023-Q3 |
| 2022-12-21 | - | Kvartalsrapport 2023-Q2 |
| 2022-10-31 | - | Årsstämma |
| 2022-10-14 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2022-09-29 | - | Kvartalsrapport 2023-Q1 |
| 2022-06-29 | - | Bokslutskommuniké 2022 |
| 2022-03-21 | - | Kvartalsrapport 2022-Q3 |
| 2022-03-15 | - | Extra Bolagsstämma 2022 |
| 2021-12-29 | - | Kvartalsrapport 2022-Q2 |
| 2021-10-20 | - | Extra Bolagsstämma 2021 |
| 2021-10-11 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2021-09-29 | - | Kvartalsrapport 2022-Q1 |
| 2021-06-24 | - | Bokslutskommuniké 2021 |
| 2021-03-16 | - | Kvartalsrapport 2021-Q3 |
| 2020-12-14 | - | Kvartalsrapport 2021-Q2 |
| 2020-10-20 | - | Årsstämma |
| 2020-10-15 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2020-09-28 | - | Kvartalsrapport 2021-Q1 |
| 2020-06-25 | - | Bokslutskommuniké 2020 |
| 2020-03-12 | - | Kvartalsrapport 2020-Q3 |
| 2019-12-17 | - | Kvartalsrapport 2020-Q2 |
| 2019-10-16 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2019-10-15 | - | Årsstämma |
| 2018-09-27 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2018-09-26 | - | Årsstämma |
| 2018-06-18 | - | Extra Bolagsstämma 2019 |
| 2018-06-12 | - | Bokslutskommuniké 2018 |
| 2018-03-12 | - | Kvartalsrapport 2018-Q3 |
| 2017-09-26 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2017-09-25 | - | Årsstämma |
| 2017-09-11 | - | Kvartalsrapport 2018-Q1 |
| 2017-06-19 | - | Bokslutskommuniké 2017 |
| 2017-03-13 | - | Kvartalsrapport 2017-Q3 |
| 2017-01-01 | - | Extra Bolagsstämma 2018 |
| 2016-11-30 | - | Kvartalsrapport 2017-Q2 |
| 2016-09-06 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2016-09-05 | - | Årsstämma |
| 2016-09-05 | - | Kvartalsrapport 2017-Q1 |
| 2016-06-13 | - | Bokslutskommuniké 2016 |
| 2016-02-22 | - | Kvartalsrapport 2016-Q3 |
| 2016-02-16 | - | Extra Bolagsstämma 2017 |
| 2015-11-30 | - | Kvartalsrapport 2016-Q2 |
| 2015-09-08 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2015-09-07 | - | Årsstämma |
| 2015-09-07 | - | Kvartalsrapport 2016-Q1 |
| 2015-06-16 | - | Bokslutskommuniké 2015 |
| 2015-03-16 | - | Kvartalsrapport 2015-Q3 |
| 2014-12-01 | - | Kvartalsrapport 2015-Q2 |
| 2014-10-07 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2014-10-06 | - | Årsstämma |
| 2014-10-06 | - | Kvartalsrapport 2015-Q1 |
| 2014-06-30 | - | Bokslutskommuniké 2014 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Phase Holographic Imaging (PHI) announces that the Company has been granted a patent on synthetic antibodies from the European Patent Office. The patent application "EP329447 Molecularly Imprinted Polymers" was submitted by PHI together with Germany's Federal Institute for Materials Research (BAM). PHI's corresponding patents in the US (https://phiab.com/phi-granted-patent-on-synthetic-antibodies-in-the-u-s/) and Japan (https://phiab.com/pressrelease/synthetic-antibody-patent-awarded-to-phi-by-japan/) were granted in 2020 and 2022, respectively.
[image]
In spring 2023, PHI established the subsidiary (https://phiab.com/pressrelease/phi-creates-a-subsidiary-for-the-anticipated-eu-patent-concerning-synthetic-antibodies/) PHI MIPS AB to house the synthetic antibody patent family. This subsidiary streamlines communication and provides transparency regarding the synthetic antibody patents, setting it apart from PHI AB's core business.
"We're pleased to have secured the synthetic antibodies patent in the US, Japan, and now the EU. In the future, our PHI MIPS AB subsidiary will enable us to explore the business possibilities of either licensing or selling the patent rights," states Patrik Eschricht, PHI CEO.
Synthetic antibodies
The granted patents protect technology for creating synthetic plastic antibodies that can be tailored to recognize and bind to specific molecules with high precision, such as identifying cancer cells in blood or tissue samples.
The synthetic antibodies are developed within the joint GlycoImaging project (https://glycoimaging.mau.se/) where PHI participated with Malmö University and four other research institutes. PHI holds the commercial rights to the innovation, owning 75 % of the patents, while Germany's Federal Institute for Materials Research (BAM) owns the remaining 25 %.
Lisa Bodily
E-mail: ir@phiab.com (ir@phiab.se)
Web: www.phiab.com - Live cell imaging & analysis